Biotech Values

[drbio45]

I may be wrong but I doubled my position today at 90 cents.

I can't believe they won't get a buyer of the entire pipeline for what we thought be be just the up front payment on the afib deal

You are correct about Multaq, apples and oranges. Half the patients on afib drugs have chf and patients and multaq is contra indicated in patients with chf.

that is why Sanofi had to do the last trial. In the prior study there were more deaths on the drug than the placebo for patients with chf